for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  PharmAsia News
  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [14 journals]
  • Japan Prices Sovaldi Well Below U.S.
    • Abstract: Japan has granted a reimbursement price to Gilead's hepatitis C drug Sovaldi as the first all-oral therapy for the disease in the country, with each pill priced well below U.S. levels but still set to cost the national healthcare insurance system upwards of $500.
      PubDate: Fri, 22 May 2015 01:50:01 -040
       
  • Big Pharma 1Q China Growth Roundup: The Winner Is…
    • Abstract: The first quarter of 2015 was marked by a further slowing down in China’s economy, lingering compliance shadows and mounting pricing pressures, which have dampened hope for a quick recovery and caused top multinational pharma executives to voice caution and moderate growth targets.
      PubDate: Thu, 21 May 2015 20:30:03 -040
       
  • Samsung Prepping For First Biosimilar Launch
    • Abstract: Samsung Bioepis's biosimilar version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) is set to become the firm’s first biosimilar product to hit the market, possibly being released in South Korea late this year and in Europe in the first half of next year.
      PubDate: Thu, 21 May 2015 19:55:00 -040
       
  • INTERVIEW: ARV Supplies At Risk If Teva Bid Succeeds, Fears Mylan
    • Abstract: At least one senior board member of Mylan is apprehensive about supplies of antiretroviral drugs (ARVs) to low income countries from the generic firm’s Indian sites should Teva succeed in its acquisition bid.
      PubDate: Thu, 21 May 2015 02:35:01 -040
       
  • Green Cross Juventas Investment Shows Gene Therapy Appetite
    • Abstract: South Korea's Green Cross Holdings has invested in the clinical-stage U.S. biotech firm Juventas Therapeutics in a bid to diversify into the cell and gene therapy sector. Along with Posco Capital, Green Cross led a $7.5 million investment in the Cleveland-based company, which focuses on developing non-viral gene therapies to treat advanced cardiovascular diseases.
      PubDate: Thu, 21 May 2015 00:15:01 -040
       
  • Local Impetus: Sri Lanka Effects Pharma ‘Buyback’ Plan
    • Abstract: Sri Lanka has implemented plans to encourage local production, with the government undertaking to "buy back" supplies of a number of specified pharmaceutical products.
      PubDate: Wed, 20 May 2015 19:20:00 -040
       
  • Japan Edges Closer To First iPSC Parkinson’s Trial
    • Abstract: Plans are moving ahead in Japan for what would be the first clinical trial globally using the country's flagship induced pluripotent stem cell (iPSC) technology to treat Parkinson's disease.
      PubDate: Wed, 20 May 2015 19:10:02 -040
       
  • INTERVIEW: Collaboration Key For China Regulatory Reforms, RDPAC Says
           (Part 2)
    • Abstract: The days when foreign investments were welcomed with open arms in China seem to be gone, and a toughening environment is setting in. As the head of the top multinational research-based pharma association in the country, RDPAC managing director Joseph Cho is looking to local partnerships to pursue regulatory reforms and expand new drug access in a rapidly changing market.
      PubDate: Wed, 20 May 2015 03:05:02 -040
       
  • Kolon’s Osteoarthritis Gene Therapy First To Move To U.S. Phase III
    • Abstract: Invossa , a cell-mediated gene therapy for knee osteoarthritis being developed by South Korea's Kolon Group, is set to begin a Phase III clinical trial in the U.S. after receiving approval from the FDA earlier this month, and appears to be the first such therapy for the indication to progress this far.
      PubDate: Tue, 19 May 2015 22:10:45 -040
       
  • B-Ingelheim NASH Deal Boosts Pharmaxis’s Revitalization
    • Abstract: The eagle has landed for Australian drug discoverer Pharmaxis in the form of a major deal with Boehringer Ingelheim for a non-alcoholic steatohepatitis (NASH) treatment, and the Sydney-based firm says it is ready to soar again following the transaction.
      PubDate: Tue, 19 May 2015 22:10:00 -040
       
  • Japan’s AMED Seeks New Mindset
    • Abstract: Japan's new Agency for Medical Research and Development (AMED) is clear on its main goals but is working to add flesh to the bones as it looks to take a matrix approach to facilitating more collaborative and speedier R&D.
      PubDate: Tue, 19 May 2015 19:25:02 -040
       
  • Add To Cart' India’s Online Pharmacy Dilemma
    • Abstract: Several Indian online pharmacies being promoted by business groups are believed to have hit the pause button against the backdrop of enforcement actions initiated by some state-level drug regulators in recent months. Some say that with no clarity on the exact legal status of online pharmacies, cases are likely to land up in the courts yet again.
      PubDate: Tue, 19 May 2015 01:15:03 -040
       
  • Aprogen’s Biosimilar Remicade To Hit Japan Next Year'
    • Abstract: South Korea-based biotech firm Aprogen's biosimilar version of Remicade (Johnson & Johnson's infliximab) is set to complete a Phase III clinical study in Japan as early as this month. The company’s Japanese partner will then file for local regulatory approval immediately after completing the trial and aims to launch the product in the country in the latter half of next year.
      PubDate: Mon, 18 May 2015 20:50:01 -040
       
  • INTERVIEW: Collaboration Key For China Regulatory Reforms, RDPAC Says
           (Part 1)
    • Abstract: The days when foreign investments were welcomed with open arms in China seem to be gone, and a toughening environment is setting in. As the head of the top multinational research-based pharma association in the country, RDPAC managing director Joseph Cho is looking to local partnerships to help pursue regulatory reforms and expand new drug access in a rapidly changing market.
      PubDate: Mon, 18 May 2015 19:20:01 -040
       
  • Turkey Regulatory Update: Vimizim Reimbursed, Rx Fraud Warning
    • Abstract: MPS patients win a vital victory against SGK, while the ministry of health warns pharmacists against a new type of fraud and nine drugs are granted reimbursement.
      PubDate: Mon, 18 May 2015 04:05:03 -040
       
  • Takeda Looks Up As It ‘Hits Bottom’
    • Abstract: Following the massive financial hit of the recent Actos settlement, Takeda appears set to return to profitable growth this fiscal year after a 12-month period during which its new CEO says the Japanese firm "hit bottom."
      PubDate: Mon, 18 May 2015 01:50:02 -040
       
  • Korean Industry Bid For Stem Cell Study Simplification Rejected
    • Abstract: South Korea’s Ministry of Food and Drug Safety has rejected a biotechnology industry demand to simplify the process to collect information on the safety and efficacy of stem cell therapies during clinical usage. From July, stem cell therapy companies will be obliged to conduct complete surveys on all patients who receive the therapies.
      PubDate: Sun, 17 May 2015 20:55:02 -040
       
  • Ex-Ranbaxy Honcho’s Ayurveda Venture Targets Migraine
    • Abstract: After decades of selling hardcore pharmaceuticals, well-known Indian industry executive Rajiv Gulati is going back to the roots of medicine, literally. His newly founded company is backing a traditional Indian concept that claims to successfully treat episodic and chronic migraines.
      PubDate: Sun, 17 May 2015 19:25:00 -040
       
  • Novo Nordisk Expecting Slower Growth In China
    • Abstract: Despite a solid first quarter in China, Novo Nordisk is predicting a slowdown in its growth in the country as the general compliance crackdown dampens promotional activities across the pharma industry.
      PubDate: Thu, 14 May 2015 20:40:01 -040
       
  • Hanmi’s Amosartan First To Benefit From Korean Linkage System
    • Abstract: Hanmi Pharm's Amosartan combination drug has been selected as the first product whose generic versions will be given nine months of marketing exclusivity under Korea’s new patent-approval linkage system.
      PubDate: Thu, 14 May 2015 20:00:04 -040
       
  • Australian Budget Uncertainty Fuels Pharma Anxiety
    • Abstract: The Australian government’s latest federal budget has fuelled anxiety within the pharmaceutical sector with its lack of detail on a much-anticipated review of subsidized medicines that is expected to slash AUD200 million of financial support for popular drugs.
      PubDate: Thu, 14 May 2015 19:55:01 -040
       
  • Brisk M&A Activity Reviving Indian CRO Scene
    • Abstract: Clinical trial approvals in India have declined sharply in recent months but that has not held back companies active in the sector – both local and global – from making acquisitions. The trend may continue as a few more deals are said to be on the anvil.
      PubDate: Wed, 13 May 2015 23:05:04 -040
       
  • Merck KGaA Joins Hands With Busan On Regenerative Medicine
    • Abstract: South Korea's Busan Metropolitan City will sign a memorandum of understanding with (MoU) Merck KGaA to set up a research and development center in the country's second largest city in a bid to join hands with the German pharma giant in the regenerative medicine sector.
      PubDate: Wed, 13 May 2015 22:25:05 -040
       
  • Takeda To Ditch Orexigen In Another Deal Exit'
    • Abstract: It's starting to look like there may be an acrimonious divorce in store for Orexigen and its marketing partner Takeda, now that the Japanese pharma has said it won't pay for another costly cardiovascular outcomes study for their obesity drug Contrave after the first was halted.
      PubDate: Wed, 13 May 2015 22:15:03 -040
       
  • Emerging Markets Remain Strong For Sanofi
    • Abstract: Sanofi has been so effective at building up its business in emerging markets these now account for around a third of the French group's total sales, and provided another quarter of strong growth despite some vaccines weakness.
      PubDate: Wed, 13 May 2015 19:15:01 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015